Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
December 07 2017 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers for patient enrichment,
today announced that Richard Murray, Ph.D., chief executive officer
and president of Jounce, will present at the BMO Capital Markets
2017 Prescriptions for Success Healthcare Conference at 4:30 p.m.
ET on Thursday, December 14, 2017 in New York.
A live webcast of the presentation will be available by visiting
“Events and Presentations” in the Investors and Media section of
Jounce’s website at www.jouncetx.com. A replay of the webcast will
be archived for 30 days following the presentation.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long‑lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within tumors
to prioritize targets, and then identifies related biomarkers
designed to match the right immunotherapy to the right patient.
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody
that binds to and activates ICOS and is currently in the Phase 2
portion of the Phase 1/2 ICONIC trial. For more information, please
visit www.jouncetx.com.
Investor Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Media Contact:Katie EnglemanPure
Communications, Inc.(910) 509-3977
kengleman@purecommunications.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024